Publication:
European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease

dc.contributor.coauthorBartoletti, M.
dc.contributor.coauthorAzap, O.
dc.contributor.coauthorBarac, A.
dc.contributor.coauthorBussini, L.
dc.contributor.coauthorKrause, R.
dc.contributor.coauthorMartin Quiros, A.
dc.contributor.coauthorPaño-Pardo, J.R.
dc.contributor.coauthorPower, N.
dc.contributor.coauthorSibani, M.
dc.contributor.coauthorSzabo, B.G.
dc.contributor.coauthorTsiodras, S.
dc.contributor.coauthorZollner-Schwetz, I.
dc.contributor.coauthorRodríguez-Baño, J.
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentKUISCID (Koç University İşbank Center for Infectious Diseases)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorErgönül, Önder
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T11:37:56Z
dc.date.issued2022
dc.description.abstractScope: despite the large availability of vaccines, coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2, continues to be a major threat for health-care providers and fragile people. A number of options are now available for outpatients with mild-to-moderate COVID-19 at the risk of disease progression for the prevention of deaths or hospitalization. Methods: a European Society of Clinical Microbiology and Infectious Diseases COVID-19 guidelines task force was established by the European Society of Clinical Microbiology and Infectious Diseases Executive Committee. A small group was established, half appointed by the chair and the remaining selected based on an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A long list of clinical questions using the population, intervention, comparison, outcome format was developed at the beginning of the process. For each population, intervention, comparison, outcome, two panel members performed a literature search, with a third panelist involved in case of inconsistent results. Voting was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Recommendations: in this update, we focus on anti-viral agents, monoclonal antibodies (mAbs) and other treatment options proposed for patients with mild or moderate COVID-19 who are at the risk of hospitalization or death. Although the use of anti-virals is recommended, especially nirmatrelvir/ritonavir and remdesivir or, alternatively, molnupirarvir, the administration of mAbs against the spike protein strictly depends on circulating variants or the ability to test timely for variants and sub-variants. At the time of writing (April–June 2022), the only active mAb was tixagevimab/cilgavimab given the predominance of the Omicron BA.2, BA.3, BA.4 and BA.5 sub-lineages in Europe. However, considering that the epidemiological scenario is extremely dynamic, constant monitoring of variants of concern is mandatory.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue12
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume28
dc.identifier.doi10.1016/j.cmi.2022.08.013
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR03819
dc.identifier.issn1198-743X
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85139318107
dc.identifier.urihttps://doi.org/10.1016/j.cmi.2022.08.013
dc.identifier.wos922899400011
dc.keywordsCilgavimab
dc.keywordsCOVID-19
dc.keywordsESCMID
dc.keywordsMolnupiravir
dc.keywordsNirmatrelvir/ritonavir
dc.keywordsOutpatients
dc.keywordsRemdesivir
dc.keywordsSotrovimab
dc.keywordsTixagevimab
dc.language.isoeng
dc.publisherElsevier
dc.relation.grantnoNA
dc.relation.ispartofClinical Microbiology and Infection
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10677
dc.subjectMedicine
dc.titleEuropean society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorErgönül, Mehmet Önder
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit1Research Center
local.publication.orgunit2KUISCID (Koç University İşbank Center for Infectious Diseases)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication09525e58-d4ea-4461-b2ec-f131e54c0771
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10677.pdf
Size:
1023.26 KB
Format:
Adobe Portable Document Format